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Abstract
Background: PINK1 deficiency causes the autosomal recessive PARK6 variant of Parkinson’s disease. PINK1 activates
ubiquitin by phosphorylation and cooperates with the downstream ubiquitin ligase PARKIN, to exert quality control
and control autophagic degradation of mitochondria and of misfolded proteins in all cell types.
Methods: Global transcriptome profiling of mouse brain and neuron cultures were assessed in protein-protein
interaction diagrams and by pathway enrichment algorithms. Validation by quantitative reverse transcriptase
polymerase chain reaction and immunoblots was performed, including human neuroblastoma cells and patient
primary skin fibroblasts.
Results: In a first approach, we documented Pink1-deleted mice across the lifespan regarding brain mRNAs. The
expression changes were always subtle, consistently affecting “intracellular membrane-bounded organelles”. Significant
anomalies involved about 250 factors at age 6 weeks, 1300 at 6 months, and more than 3500 at age 18 months in the
cerebellar tissue, including Srsf10, Ube3a, Mapk8, Creb3, and Nfkbia. Initially, mildly significant pathway enrichment for the
spliceosome was apparent. Later, highly significant networks of ubiquitin-mediated proteolysis and endoplasmic
reticulum protein processing occurred. Finally, an enrichment of neuroinflammation factors appeared, together with
profiles of bacterial invasion and MAPK signaling changes—while mitophagy had minor significance.
Immunohistochemistry showed pronounced cellular response of Iba1-positive microglia and GFAP-positive astrocytes;
brain lipidomics observed increases of ceramides as neuroinflammatory signs at old age.
In a second approach, we assessed PINK1 deficiency in the presence of a stressor. Marked dysregulations of microbial
defense factors Ifit3 and Rsad2 were consistently observed upon five analyses: (1) Pink1−/− primary neurons in the first
weeks after brain dissociation, (2) aged Pink1−/− midbrain with transgenic A53T-alpha-synuclein overexpression, (3) human
neuroblastoma cells with PINK1-knockdown and murine Pink1−/− embryonal fibroblasts undergoing acute starvation, (4)
triggering mitophagy in these cells with trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP), and (5) subjecting
them to pathogenic RNA-analogue poly(I:C). The stress regulation of MAVS, RSAD2, DDX58, IFIT3, IFIT1, and LRRK2 was
PINK1 dependent. Dysregulation of some innate immunity genes was also found in skin fibroblast cells from PARK6
patients.
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Conclusions: Thus, an individual biomarker with expression correlating to progression was not identified. Instead, more
advanced disease stages involved additional pathways. Hence, our results identify PINK1 deficiency as an early modulator
of innate immunity in neurons, which precedes late stages of neuroinflammation during alpha-synuclein spreading.
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Background
Parkinson’s disease (PD) is the second most prevalent neu-
rodegenerative disease after Alzheimer’s disease (AD). An
autosomal recessive variant of PD, PARK6, is caused by
loss-of-function mutations in PINK1 (PTEN-induced
kinase 1) [1]. PINK1 activates ubiquitin by phosphorylation
[2–4] and exerts quality control over mitochondria,
controlling their translational repair, fusion, and elimination
by mitophagy [5–9]. In this role, it cooperates with the
downstream ubiquitin ligase PARKIN, which is responsible
for another autosomal recessive variant of PD, named
PARK2 [10–12].
Independent from their role for mitochondria, PINK1
and PARKIN are transcriptionally induced by trophic
and nutrient deprivation stress [13, 14], and they influ-
ence the trophic cell state through modulation of the
signaling from glial cell line-derived neurotrophic factor
(GDNF) and its receptor tyrosine kinase RET [15–17].
Unexpectedly, PARKIN was recently discovered to
modulate also the cellular resistance against microbial
invasion [18].
Thus, in spite of the deep knowledge about the roles of
PINK1 and PARKIN for selective mitophagy, there is an
important need to conduct unbiased surveys to elucidate
additional functions of PINK1 and PARKIN in stress
responses. Our previous OMICS work observed only mild
changes in mRNA, protein abundance and posttranslational
modifications in response to PINK1 loss-of-function, failing
to identify individual biomarkers that correlate with disease
progression [19–22].
Transcriptome dysregulations below 1.5-fold are usu-
ally regarded with skepticism and are difficult to validate
with other experimental techniques. However, in age-
associated neurodegenerative disorders, they cannot be
disregarded. It is known that the 1.5-fold increase of
beta-amyloid precursor protein (APP) dosage on
chromosome 21 leads to typical AD symptoms and
neuropathology already by the age of 40 years in most
Down syndrome cases [23], so the triggers of any AD
manifestation at ages 60–90 must be equivalent to an
APP gene dosage much smaller than 1.5-fold. Similarly,
the manifestation of PD is triggered by alpha-synuclein
around age 35 years via a twofold gene dosage increase
[24], around age 50 via a 1.5-fold gene dosage [25], and
around age 70 by a 1.3-fold gene dosage [26, 27]. In
practically all chromosomal trisomies, the 1.5-fold
increase in dosage of some genes results in embryonal
lethality, so any old-age pathology triggered from
these genes would result from <1.5-fold expression
dysregulation.
The relevance of subtle expression changes has been
taken into account by modern analysis tools based on “gene
set enrichment analyses” [28]. Therefore, we now re-
investigated our global transcriptome data with automated
biomathematics tools, accepting that some false positive
and false negative results will have to be dealt with, but
hoping that the significant enrichment of pathways and
subcellular compartments will identify PINK1-deficiency ef-
fects that are validated by the consistency over time as well
as across tissues and species.
For this aim, we (1) analyzed the global transcriptome
profile of Pink1−/− mouse brain tissue at three ages, (2)
surveyed Pink1-dependent regulations of the global tran-
scriptome in neuron-rich primary cultures from postnatal
mouse brain at 12 days after the acute brain dissection
stress, (3) validated the results in aged Pink1−/− brain
where the transgenic overexpression of A53T-alpha-
synuclein (gene symbol SNCA) exerted chronic neuro-
toxic stress, (4) tested the cellular response of microglia
and astrocytes in Pink1−/− brain by immunohistochemis-
try, (5) used lipidomics to study pro-inflammatory signals,
(6) performed a systematic assessment of the expression
of key factors of antiviral state in human neuroblastoma
cells with lentiviral PINK1-Knock-Down (KD), studying
the time course after acute starvation stress, (7) re-
assessed the same key factors of antiviral state in human
PINK1-(KD) neuroblastoma versus Pink1−/− murine em-
bryonal fibroblasts after mitophagy via FCCP drug treat-
ment, and (8) tested the same factors after stress with the
pathogenic poly(I:C) RNA regarding PINK1-dependent
expression regulation. Primary skin fibroblasts from three
patients at advanced age with manifest PD due to G309D-
PINK1 mutations were employed to assess the relevance
of these data for the human disease.
Methods
Mouse breeding and brain dissection
Pink1−/− and wildtype (WT) control mice, which were
derived from common ancestors and share the strain
129/SvEv genetic background, were bred and genotyped
as previously reported [29]. Brain tissue from Pink1−/−
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+A53T-SNCA double mutant mice was obtained as pub-
lished [20].
Global transcriptomics
Affymetrix oligonucleotide microarray profiling was per-
formed with Genechip mouse genome 430 2.0 arrays as
previously [30, 31], using cRNA from the brain cerebel-
lar tissue as reported before [20] and from neuron-rich
primary cultures from 3 Pink1−/− versus 3 age and sex-
matched WT control mice. Hybridization occurred on
Affymetrix Genechip mouse genome 430 2.0 arrays,
which represent 39,000 transcripts, of which more than
half are anonymous or poorly understood, according to
PubMed and GeneCards database searches. The
biomathematical analysis was performed in the institute
for medical genetics at Tuebingen University.
Bioinformatic analyses
For protein-protein interaction (PPI) network analysis, the
software tool String v.10 (https://string-db.org/) with
standard settings has been employed to visualize networks
of significant dysregulations [32]. As recommended, gene
symbols of factors with significant dysregulation were
entered into the Multiple Proteins window with the Mus
musculus option, the matching of the input with the
correct factors was accepted, and the graphic interaction
diagram was generated and archived. The Analysis button
was used to generate automated network statistics;
significant functional enrichments of GO (Gene
Ontology) terms and KEGG pathways were exported
into EXCEL files.
For an additional comprehensive transcriptome ana-
lysis, gene set enrichment analysis (GSEA, v2.2.3,
http://software.broadinstitute.org/gsea/index.jsp) [28]
was applied in order to see, if a priori defined sets of
genes show statistically significant, concordant differences
between mutant/WT in 18 months old cerebellum samples.
For every gene, only the one entry with the lowest adjusted
p value and the according log2 transformed ratio was taken.
GSEA default settings and Reactome v5.2 and KEGG v5.2
gene set database were used. Pathways with p value ≤0.05
and FDR q ≤ 0.25 were regarded as significant. Heat maps
were produced with the Perseus software.
Primary neuron culture
Neuron-rich primary cultures from the dissociated brain
cerebral cortex of postnatal mice were prepared as previ-
ously described [33]. In short, 500,000 cells per well
were seeded on a 0.01% (w/v) poly-D-lysine coated 6-
well plate. In order to limit the growth of dividing cells,
cytosine ß-D-Arabinoside was added on the second day
of culture as before. The 3 plate pairs (mutant versus
WT), where many singular neurons in homogeneous
density with a dense network of processes contrasted
with very few astrocytes and microglia present, were
chosen out of a total of 12 plate pairs on culture day 12
for RNA extraction.
Brain homogenate from aged mice
Mouse aging and dissection of mice was carried out as be-
fore, employing cerebellum from single mutant Pink1−/−
at three ages (10 mutants versus 10 WT) and midbrain
from adult double mutant Pink1−/−+A53T-SNCA mice at
age 18 months (5 mutants versus 5 WT) for the extraction
of global RNA and cDNA synthesis [20].
GFAP and Iba1 immunohistochemistry
Immunohistochemistry was performed using an automated
staining system (Leica Bond-III, Nussloch, Germany). The
following antibodies were used: anti-GFAP, rabbit
polyclonal antibody, dilution 1:14,000 (DakoCytomation,
Glostrup, Denmark); anti-Iba1, rabbit antibody, dilution
1:1000 (Wako Pure Chemical Industries, Osaka, Japan).
Representative areas of striatum, substantia nigra,
neocortex, and brainstem of Pink1−/− (n = 1) and wild-
type (n = 1) animals were analyzed using ImageJ soft-
ware (Version 1.51 h; National Institutes of Health, Be-
thesda, Maryland, USA). We quantified positive cells in
relation to all cells.
Tissue preparation for lipid analysis
Matched pairs of male and female Pink1−/− and Pink1+/+
mice were used for analysis of bioactive lipids in brain
tissue. Mice were 9–13 months (four each), 17 months
(three each), and 21 months (four each) old at the time
of tissue preparation (mean age 15.5 −/− and 17 +/+).
Mice were sacrificed by carbon dioxide. Blood was
drawn into K+ EDTA microvettes (Sarstedt) for plasma
analysis by cardiac puncture. Subsequent intracardial
perfusion with saline removed rests of blood. The lum-
bar spinal cord, olfactory bulb, and hippocampus were
dissected, and tissue pieces of 3–5 mg were excised, rap-
idly frozen in liquid nitrogen, and stored at −80 °C until
analysis. The precise tissue weight was determined on
precision scales directly before tissue homogenization.
Analysis of lipid signaling molecules
Sphingolipids were analyzed by liquid chromatography
tandem mass spectrometry (LC-MS/MS) in different re-
gions of the nervous system (olfactory bulb, hippocam-
pus, spinal cord) at three different ages (8.5–12.5 weeks,
17.5 weeks, and 21 weeks). LC-MS/MS analyses were
done on an API4000 triple quadrupole mass spectrom-
eter equipped with an APCI (atmospheric pressure
chemical ionization) ion source for the analysis of cera-
mides and with an ESI (Electrospray Ionization) ion
source for the analysis of sphingosines, Glu-Cer/Lac-Cer
(Sciex, Darmstadt, Germany) [34, 35]. All quadrupoles
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were working at unit resolution. Concentrations of the
calibration standards, quality controls, and samples were
evaluated by MultiQuant 3.0 (Sciex, Darmstadt,
Germany) using the internal standard method (isotope-
dilution mass spectrometry). Calibration curves were
calculated by linear regression with 1/x weighting. The
coefficient of correlation for all measured sequences was
at least 0.99.
Tissue pieces of approximately 4 mg were homoge-
nized in 200-μl extraction buffer (50 μl per mg). For
analysis of sphingolipids, 20 μl plasma or homoge-
nized tissue samples consisting in 0.4 mg tissue were
extracted with methanol:chloroform:HCl (15:83:2)
after spiking with the respective internal standards,
which was Cer17:0 for ceramides and sphingosine-D7
and sphingosine-1-phosphate-D7 for sphingosines. A
Luna C18 column (150 mm × 2 mm ID, 5 μm par-
ticle size, 100 Å pore size; Phenomenex, Aschaffen-
burg, Germany) was used for chromatographic
separation. The HPLC mobile phases consisted of
water-formic acid (100:0.1, v/v) (A) and acetonitrile-
tetrahydrofuran-formic acid (50:50:0.1, v/v/v) (B). For
separation, a gradient program was used at a flow
rate of 0.3 ml/min. The initial buffer composition was
60% (A)/40% (B). It was maintained for 0.6 min, then
linearly changed to 0% (A)/100% (B) over 3.9 min,
and held for 6.5 min. Subsequently, the ratio was
linearly changed back within 0.5 min to 60% (A)/40%
(B) and then held for another 4.5 min. The running
time for every sample was 16 min. The injection vol-
umes were 15 μl for ceramides and 10 μl for sphingo-
sines. The analyses were done in multiple reaction
monitoring (MRM) mode. For every analyte, two tran-
sitions were recorded, one for quantification and the other
for identification. The peak area of the analyte was nor-
malized for the peak area of the internal standard.
Precursor to product ion transitions for quantification
were: m/z 539 → 264 for C16:0-Cer, m/z 567 → 264 for
C18:0-Cer, m/z 595 → 264 for C20:0-Cer, m/z 651 → 264
for C24:0-Cer, m/z 649 → 264 for C24:1-Cer, m/z
700 → 264 for C16:0-GluCer, m/z 729 → 264 for C18:0-
GluCer, m/z 862 → 264 for C16:0-LacCer, m/z 891 → 264
for C18:0-LacCer, m/z 973 → 264 for C24:1-LacCer, m/z
553→ 264 for C17:0-Cer, m/z 300→ 282 for Sph and m/z
380→ 264 for S1P. The dwell times were 15 or 50 ms.
To assess genotype-dependent differences on individ-
ual ceramides in specific regions, mice of different ages
were summarized. To assess progression over age, cera-
mides across regions were pooled, log2-transformed to
linearize the data, and subsequently summed to get a
global readout for all ceramides. Total ceramides were
then plotted over time and genotype-dependent differ-
ences at different ages were analyzed using two-way
ANOVA for “genotype x age”.
Neuroblastoma starvation
The human SH-SY5Y neuroblastoma cell line with
dopaminergic properties was stably transduced by
lentivirus either with a control (NT for Non-Target
knock-down) shRNA or a shRNA directed against
PINK1 and maintained under puromycin (1 μg/ml)
selection in RPMI medium containing 10% Fetal Calf
Serum (FCS), as published already [6]. These PINK1-
KD and NT control cell lines had the stability of their
KD controlled repeatedly over many months. They
were switched to HBSS medium without FCS, to sub-
ject them to a starvation time course as previously
described [13].
Quantitative reverse transcriptase real-time polymerase
chain reaction (qPCR)
RNA was isolated with the RNeasy mini kit (Qiagen)
and then treated with DNase I. cDNA was synthesized
with SuperScript III reverse transcriptase using oli-
go(dT)20 and random primers (Invitrogen). cDNA from
20 to 25 ng RNA were utilized in a 20 μl reaction vol-
ume using the StepOnePlus Real-Time PCR System and
the appropriate murine (lowercase) or human (upper-
case) TaqMan gene expression assays (Applied Biosys-
tems): for mouse Pink1 (Mm00550827_m1), Creb3
(Mm00501607_m1), Ddx58 (Mm01216853_m1), Hebp1
(Mm00469161_m1), Ifit1 (Mm00515153_m1), Ifit3
(Mm01704846_s1), Irf3 (Mm00516784_m1), Mapk8
(Mm01218957_m1, Mm01218946_m1, Mm0048951
4_m1), Mapk9 (Mm00444239_m1), Mapk14 (Mm01
301009_m1), Mavs (Mm00523170_m1), Mfn1 (Mm00
612599_m1), Nfkbia (Mm00477798_m1), Rsad2 (Mm00
491265_m1), Srsf10 (Mm01193320_m1), Tbk1 (Mm004
51150_m1), Tnf (Mm00443258_m1), for human PINK1
(Hs00260868_m1), DDX58 (Hs01061436_m1), HEBP1
(Hs00211123_m1), IFIT1 (Hs03027069_s1), IFIT3 (Hs0
0155468_m1), IRF3 (Hs01547283_m1), LRRK2 (Hs004
11197_m1), MAVS (Hs00920075_m1), MFN1 (Hs0096
6851_m1), RSAD2 (Hs00369813_m1), SQSTM1 (Hs00
177654_m1), TBK1 (Hs00179410_m1). mRNA expres-
sion was normalized to the TATA binding protein gene
expression or the Hypoxanthine Phosphoribosyltransfer-
ase 1 gene expression (Tbp: Mm00446973_m1, TBP:
Hs99999910_m1, HPRT1: Hs99999909_m1). Relative
expression changes were calculated with the 2−ΔΔCt
method [36].
Triggering mitophagy via treatment with FCCP
The drug FCCP, which is known to uncouple the
mitochondrial membrane gradient and trigger mito-
phagy [37], was administered over 24 h at 10 μM
concentration to human SH-H5Y neuroblastoma cells
or murine embryonal fibroblasts, which had been cul-
tured in DMEM plus 10% FCS and grown to
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confluency (approximately 4 × 106 cells) in T25 flasks
as previously described [38]; then, the cells were col-
lected, and the RNA was extracted with TRIzol
methodology.
Stressing cells with a pathogenic RNA-analogue
The synthetic dsRNA polymer poly(I:C), which induces
the RNA sensors that activate innate immunity [39, 40],
was purchased from InvivoGen in the low molecular
weight variant with the transfection agent LyoVec and
used at a concentration of 1 μg/ml (for SH-SY5Y cells)
or 2 μg/ml (for MEFs) as recommended by the manufac-
turer during 16 h before harvesting the cells and extract-
ing RNA/protein.
Human primary skin fibroblast cultures
Previously established primary skin fibroblast cultures
from 3 homozygous PARK6 patients (passages 12–14)
were employed as published [12, 19, 41–43], in addition
to one sex-/age-matched control (the principal investiga-
tor G.A., passage 14) and four matched control fibro-
blast lines from Coriell depository (catalog number
AG02261/passage 6/age 61, AG06103/passage 16/age 29,
AG06858/passage 5, age 47, AG12207/passage 14/age
68).
Quantitative immunoblotting
The isolation of total proteins from the primary skin fibro-
blasts was carried out as described [42]. Samples of 20 μg
were heated at 90 °C for 5 min and then separated in 10%
tris–glycine polyacrylamide gels, using Precision Plus
Protein™ All Blue Standards as size marker. Transfer to
nitrocellulose membranes (Protran, GE Healthcare) was
done at 50 V for 90 min, with blocking in 5% BSA solution
in 1X TBS-T for 1 h at room temperature (RT). Primary
antibodies against LRRK2 (1:1000, NBP1–49954, Novus),
IFIT3 (1:500, 15,201–1-AP, Proteintech), IFIT1 (1:500,
23,247–1-AP, Proteintech), DDX58 (1:700, 3743, Cell
Signaling Tech), RSAD2 (1:500, 11,833–1-AP,
Proteintech), and β-Actin (1:5000, A5441, Sigma-Aldrich)
occurred in 1X TBS-T solutions overnight at 4 °C.
Fluorescent-labeled α-mouse (1:15,000, IRDye 800CW,
Li-Cor) and α-rabbit (1:15,000, IRDye 680RD, Li-Cor)
were the secondary antibodies. Fluorescence detection oc-
curred on the Li-Cor Odyssey Classic Instrument.
Statistical analyses
Statistical significance was assessed using ANOVA or
unpaired t test with Welch’s correction in the GraphPad
Prism 5 software.
Results
Global transcriptome profile of Pink1−/− mouse brain and
its progression during aging
Previously, we documented the effects of PINK1 defi-
ciency on brain regions such as midbrain, striatum, and
cerebellum at different ages in the absence of stress or in
the presence of A53T-alpha-synuclein overexpression as
stressor, identifying marked effects of PINK1-deficiency
on mitochondrial biology and excitability via global
transcriptome profiles [20–22, 29, 44]. Irrespective of the
size of fold-changes, we now document all significant
expression dysregulations in Pink1−/− brain, which were
consistent (1) across the lifespan and (2) across diverse
brain areas (Additional file 1: Table S1). As expected, the
loss of Pink1 transcript constituted the most significant
effect, being detected by two microarray probesets. An
additional downregulation was observed for the splicing
repressor Srsf10 (also called Fusip1) (to 63% on average), a
stress response factor which regulates the levels of the
inflammasome component Caspase 1 [45]. A downregula-
tion was found also for the vesicle endocytosis factor Clta
(to 32%), which controls antibody isotype switching [46]. A
converse upregulation was documented by two independ-
ent probesets for the splicing activator Srrm1 (to 187%),
which is responsible for splicing of the lymphocyte surface
protein CD44 [47]. Another upregulation detected by two
independent oligonucleotide probesets appeared for the
precursor RNA processing factor Hnrnpr, which is known
to regulate c-Fos and thus neuronal excitability, but also
the expression of classical and non-classical MHC class I
proteins (probeset 2610528B01Rik showing transcript ele-
vation to 172% and probeset Gm17388 to 131%) [48, 49].
Currently, there is almost no experimental evidence impli-
cating PINK1 in splicing [22] or in endocytosis [50].
Against our expectations, these expression dysregulations
did not increase with age, so the fold-changes at age
18 months were very similar to those at 6 weeks. Thus, the
focus on the expression of individual transcripts failed to
identify markers of pathology progression.
Bioinformatic pathway analysis: Gene Ontology
Enrichment by STRING
To further elucidate the expression effects of PINK1-
deficiency in nervous tissue, we now considered the
enrichment of functional pathways and of protein inter-
action networks, employing automated bioinformatics
tools. This approach was focused on the cerebellum, in
view of several advantages: (1) The cerebellum is rela-
tively big and easy to dissect with negligible anatomical
variance; (2) its expression changes will not get diluted
as in other brain regions where substantial neuron
population heterogeneity renders many effects minimal
upon mixed tissue analysis; and (3) it does not suffer
from the neuron loss and astrogliosis, which are
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expected to occur in the vulnerable brain regions of PD
models and which would distort expression profiles.
To illustrate the impact of PINK1 deficiency on specific
gene networks within the global cerebellar transcriptome
and to visualize the progression from age 6 weeks via
6 months until age 18 months, we produced a STRING
diagram of protein-protein interaction clusters for each
age (Additional file 2: Fig. S1A–S1C). In these figures, it is
evident that the progression of pathology involves pro-
gressively increasing numbers of individual factors and
pathways, so that at age 18 months, only the most severe
effects could be visualized.
In mice at age 6 weeks, around 250 factors showed sig-
nificant expression changes (with false discovery rate, FDR,
adjusted p value below 0.05) in Affymetrix oligonucleotide
microarray studies (Additional file 3: Table S2A, first data-
sheet). Their analysis regarding the enrichment of specific
pathways and protein-protein interactions with the
automated bioinformatics tools at the STRING web-
server detected significant dysregulation for 158 mole-
cules within the Gene Ontology (GO) Cellular Com-
ponent term “intracellular membrane-bounded
organelle” (FDR q value = 6.39e−08) (Additional file 3:
Table S2B), in good consistency with the known mito-
chondrial localization of PINK1 protein during stress.
Interestingly, an enrichment was notable for the
KEGG pathway “Spliceosome” (q value = 0.04 only, in
view of the few dysregulations at this initial stage of
pathology) (a blown-up interaction diagram detail
around the splicing factor Sfrs10 is shown in Fig. 1a).
The STRING diagram (Fig. 1a, Additional file 2: Fig. S1A),
which represents this age, shows the intracellular
membrane-bounded organelle factors highlighted in
red color.
Fig. 1 Details from the STRING interaction diagrams within the global transcriptome profiles of Pink1-deficient mouse cerebellar tissue. a At age
6 weeks, a network of splicing factors around Srsf10 was dysregulated. Red symbols indicate membrane-associated factors. The complete profile
interaction diagram can be found in Additional file 2: Fig. S1A. b At age 18 months, a much denser network including inflammatory factors like
Creb3, Irf3, Nfkbia, Mapk8, Mapk9, and Stat1 was dysregulated. Components of the “Toll-like receptor signaling pathway” factors are highlighted in
red color. The complete profile interaction diagram can be found in Additional file 2: Fig. S1C
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In mice at age 6 months, over 1300 factors showed
expression changes at this significance threshold
(Additional file 3: Table S2A, second datasheet). Their
bioinformatics analysis detected significant dysregula-
tion for 826 molecules within the GO Cellular
Component term "intracellular membrane-bounded organ-
elle" (q value = 7.61e−16) (Additional file 3: Table S2C).
Significant enrichment in the KEGG pathways “Ubiquitin-
mediated proteolysis” (q = 1.01e−05) and “Protein
processing in endoplasmic reticulum” (q = 3.34e−04) were
notable. The corresponding STRING protein interaction
diagram (Additional file 2: Fig. S1B) for this age again
shows the intracellular membrane-bounded organelle
factors highlighted in red color.
In mice at age 18 months, about 3500 factors showed ex-
pression changes at this significance threshold, too many to
be processed by STRING bioinformatics (its limit is at 2000
nodes). Thus, only the about 1600 dysregulated factors with
an adjusted p value below 0.01 were analyzed regarding in-
teractions and enrichments (Additional file 3: Table S2A,
third datasheet). Significant enrichment for 1031 molecules
within the GO Cellular Component term intracellular
membrane-bounded organelle (q value 6.34e−67) was
detected (Additional file 3: Table S2D). At this stage of
progression, significant enrichment was observed in several
GO biological processes (Additional file 3: Table S2E),
particularly 537 factors in “cellular response to
stimulus” (q value 2.82e−14), 165 factors in “cellular
response to stress” (q value 1.02e−09), and 23 factors
in “regulation of mitophagy” (q value 0.038). These
data are in agreement with the notion that the
well-documented role of PINK1 in mitophagy is a
small part of a much broader role of PINK1 in
stimulus-dependent signaling and in stress responses.
Significant enrichment was also observed in multiple
KEGG pathways (Additional file 3: Table S2F),
prominently for 47 factors in the “MAPK signaling
pathway” (q value 2.64e−06), for 32 factors in the "ubi-
quitin-mediated proteolysis pathway" (q value 2.64e
−06), for 34 factors in the "Protein processing in endoplas-
mic reticulum" pathway (q value 1.68e−05), and for 20
factors in the “Bacterial invasion of epithelial cells”
pathway (q value 6.37e−05). Mildly significant was the en-
richment of 21 factors of the “Dopaminergic synapse”
pathway (q value 0.005), 16 factors of the “GABAergic
synapse” pathway (q value 0.008), and 18 factors of the
“Glutamatergic pathway” pathway (q value 0.015). These
data are in excellent consistency with previously estab-
lished roles of PINK1 as a component of MAPK signaling
[51, 52], as an activator of PARKIN which prevents bacter-
ial invasions [18], and as a modifier of dopaminergic,
GABAergic, and glutamatergic signaling in the nigrostria-
tal pathway [44, 53–56]. The agreement of our bioinfor-
matics analysis of the global transcriptome with previously
published cell biology data provides credibility to this au-
tomated approach.
In the STRING interaction diagram of cerebellar tran-
scriptome changes at age 18 months, the appearance of
neuroinflammatory factors was highlighted, manually pla-
cing the components of the significantly enriched KEGG
pathways “HTLV-I infection”, “Toll-like receptor signaling”,
“TNF signaling pathway”, “Fc epsilon RI signaling”, “T cell
receptor signaling pathway”, “RIG-1-like receptor
signaling”, “Hepatitis C”, and “Influenza A” in the lower left
corner and highlighting the Toll-like receptor signaling
pathway factors in red color (Additional file 2: Fig. S1C). A
detail of this interaction diagram with focus on the inflam-
matory factors Creb3, Irf3, Nfkbia, Mapk8, Mapk9, and
Stat1 is shown in Fig. 1b.
Heat maps were then used to focus on prominent
examples among the significantly altered pathways,
representing each dysregulated component at the
three ages, not only for the Parkinson-resistant cere-
bellar tissue but also for comparing the Parkinson-
vulnerable midbrain/brainstem and striatum (Table 1).
This approach visualizes the temporal and spatial ap-
pearance of pathology as well as the effect sizes in a
color code, with deep red mirroring strong upregula-
tions and deep blue shades for strong downregula-
tions. It also illustrates the number of factors and
possibly the relevance of each pathway. Although the
effect of PINK1 on ubiquitin-mediated proteolysis and
on mitophagy are excellently studied, providing proof
of principle that these moderate changes of many
pathway components are relevant, it was novel to de-
tect a selective dysregulation in particular for Ube3a
that has a known role in the degradation of cytoplas-
mic misfolded proteins like alpha-synuclein [57–59],
for Xiap with an established function in ubiquitina-
tion, mitochondrial apoptosis, and innate immunity
[60], for Dnm1l (encoding DRP1) with previously
defined effects on PINK1-dependent mitochondrial
fission [7, 61], as well as for Slc6a1 as a GABA transporter
known to be induced by neuroinflammation [62]. The re-
gional comparison in Table 1 made it evident that PINK1-
deficiency-mediated downregulations of stress-response
factors dominate in the PD-resistant cerebellar tissue,
while the same factors show converse progressive upregu-
lation in the PD-affected midbrain/brainstem tissue, e.g.,
Keap1, Mbtps1, Rad23a, Sec61a1, Hif1a, Pi4k2a, the
autophagy factors Map1lc3b and Sqstm1. Further opposing
regulations occurred for the ubiquitin-binding factor Tollip,
which regulates Toll-like receptor signaling as well as the
autophagic clearance of ubiquitin conjugates and protein
aggregates [63]. This supersensitive upregulation in tissues,
which are known to suffer PD-specific stress, might repre-
sent a cellular effort to compensate PINK1 deficiency
further downstream.
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If the STRING analysis is conducted with high
stringency only for those cerebellar factors, which are
significantly downregulated with >1.5-fold change, then
much information is lost and the KEGG pathway of
MAPK signaling becomes prominent at the different ages
(Additional file 4: Table S3). This marked effect is not un-
expected, since PINK1 (short for PTEN induced kinase 1)
is downstream of PTEN, a phosphatase that antagonizes
the kinase PI3K, which is an upstream modulator of the
MAPK phosphorylation cascade at various levels.
Furthermore, the interaction of PINK1 with the MAPK
pathway has already been demonstrated experimentally in
neuroblastoma cells, astrocytes, HeLa, and HepG2 liver
cells [51, 64–66].
Bioinformatic pathway assessment by Gene Set
Enrichment analysis
Going even further, instead of considering only the ex-
pression dysregulations beyond a significance threshold,
we employed a tool that takes all genes with their ex-
pression ratios into account to compare them with
known gene sets of functional relevance. This approach
even recognizes compound effects, when most compo-
nents of a pathway are subtly dysregulated in the same
direction. This Gene Set Enrichment Analysis (GSEA)
software thus performs a comprehensive assessment of
the complete transcriptome data and is useful as an in-
dependent complement of the STRING approach. In the
cerebellum, the most salient result was a significant ef-
fect for the KEGG pathway “Parkinson’s disease”, but
this biomathematical finding was mainly due to the loss
of Pink1 transcript. Again, at the age of 6 weeks among
the KEGG pathways, spliceosome downregulation
appeared prominently (Additional file 5: Table S4).
Downregulations of “Antigen processing and presenta-
tion” as well as "Ubiquitin-mediated proteolysis" were
already significant. Among the Reactome pathways at
this age, downregulations in the “innate immune system”
already had nominal significance. At the age of 6 months,
again an impairment of "endoplasmic reticulum stress
responses" appeared with a significant downregulation of
the Reactome pathway “Activation of chaperone genes
by Xbp1s”. At the age of 18 months, among the
Reactome pathways, “antiviral mechanism by IFN stimu-
lated genes” became prominent, and in particular the
“Negative regulators of RIG I and MDA5 signaling” just
touched significance in FDR. For the maximal pathology
at the age of 18 months in the cerebellum, the top dozen
dysregulated pathways from the KEGG database and the
top dozen dysregulated pathways from the Reactome
database were documented with individual components
and their expression scores (Additional file 6: Table S5).
Moreover, four Reactome pathways with special relevance
for this manuscript were analyzed in their progressive
Table 1 Global transcriptome analysis with prominent pathway
dysregulations upon STRING assessment at 3 ages in different
brain regions of Pink1−/− mice, illustrated as heat maps
Expression dysregulations in Affymetrix microarrays are shown in different brain
regions (C = cerebellum, M = midbrain, S = striatum) across the mouse lifespan
(6 W = 6 weeks, 24 W = 24 weeks = 6 months, 18 M = 18 months), for genes
detected by a specific oligonucleotide probe ID, together with the Adjusted
p values (AdjPval) as determined by Affymetrix transcriptome bioinformatics via
software platform R and the bioconductor package Limma. Displayed are the genes
contained in five exemplary pathways, which exhibited significant enrichment
according to STRING bioinformatics, as indicated by the false discovery rate q
values. The ranked order of all dysregulated pathways upon STRING assessment can
be found in Additional file 3: Table S2
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dysregulation by heat maps (Additional file 7: Table S6).
Thus, the temporal order of pathway involvement and the
late-stage prominence of neuroinflammation were repro-
ducible in an alternative approach.
qPCR validation of candidate dysregulations in aged
Pink1−/− mouse cerebellum
Experimental validation was performed for several dysregu-
lated components of these pathways. As shown in
Additional file 8: Fig. S2A, a significant downregulation was
confirmed for the stress responsive splicing factor Srsf10
[67], while significant upregulations were observed for the
cerebellar mRNA levels of Creb3 (human LZIP, synonym-
ous LUMAN), which influences endoplasmic reticulum
protein processing [68, 69], and for Nfkbia (NF-Kappa-B in-
hibitor alpha), which cooperates with Creb3 to modulate
the nuclear control of stress and inflammation responses
[70–73], but not for other candidates within the Mapk
(MAP kinase) gene family (Additional file 8: Fig. S2A). Of
particular interest was the dysregulation of Ube3a within
the ubiquitination pathway, because only one splice isoform
changed its expression, which might be target of the spli-
ceosome adaptation observed above, and because UBE3A is
involved in the degradation of alpha-synuclein as the main
driver of Parkinson pathogenesis [59].
We then focused on JNK1 (Mapk8 mRNA) expression,
a crucial component of the stress-dependent phosphoryl-
ation cascades that control endoplasmic reticulum protein
processing, neuroinflammation, and apoptotic or autopha-
gic cell death [74–77]. JNK1 activity is also regulated by
alternative splicing [78, 79]; therefore, three representative
exon-exon junctions were assessed. Quantitative reverse
transcriptase PCR (qPCR) in Pink1−/− cerebellum at age
18 months in the absence of additional stressors demon-
strated a significant but mild upregulation, 1.15-fold ±0.04
SEM with p = 0.01 (Additional file 8: Fig. S2B). This
finding is consistent with a previous report of increased
p38 MAPK activation in PINK1-deficient mouse astro-
cytes [51]. However, the expression change of JNK1 was
too subtle to be validated by quantitative immunoblots.
This technique has inherent variability and limited linear-
ity, so it requires an impractically high number of samples
to detect 1.1-fold changes. Thus, a subtle dysregulation of
the spliceosome pathway, the endoplasmic reticulum pro-
tein processing pathway, and neuroinflammatory response
pathways was observable in global microarray transcrip-
tome profiles upon unbiased bioinformatics analyses in
old Pink1−/− mouse cerebellum, and the alteration of these
pathways could be validated experimentally by qPCR for
several key factors.
Overall, PINK1 deficiency triggered a dysregulated
expression of many membrane-associated factors already in
the first weeks of life. The progression of pathology
occurred mainly through involvement of more pathways
and protein interaction networks, rather than through
stronger expression dysregulation. Pathological mitophagy
and neuroinflammation profiles were apparent by the age
of 18 months in Pink1−/− cerebellum.
Activation of the cellular immune response in Pink1−/−
mouse brain
To test if the molecular profile of immune activation is
reflected by cellular responses in the brain tissue, immu-
nohistochemistry of GFAP as marker of astroglia and of
Iba1 as marker of microglia was performed. Parallel pro-
cessing of the sections was necessary to visualize their
subtly increased immunoreactivity in diverse areas of the
Pink1−/− brain, which was prominent at the myelinated
fiber tracts, e.g., the corticospinal projections through the
striatum, the brainstem, and also in the cerebellar white
matter (Fig. 2a, b). This increase was not detectable in nu-
clei like the striatal matrix or the substantia nigra and was
not consistent in the cerebral cortex upon counting react-
ive cells in sections at even intervals throughout the brain
(Fig. 2c). Thus, the dysregulation of membrane-associated
factors in old animals leads to a cellular immune response
most likely at myelinated axons.
Accumulation of ceramides in Pink1−/− mouse brain
To further assess the relevance of the subtle transcriptional
changes at the effector molecule level, we decided to
analyze ceramides of different chain lengths and saturation
and their sugar-modified metabolites because ceramides
trigger lethal mitophagy [80], lactosyl-ceramides maintain
neuroinflammation [81], and ceramides accumulate upon
lysosomal dysfunctions and LRRK2-deficiency [82] and are
expelled by activated astrocytes via exosomes [83]. Hence,
ceramide pathology may be a key factor for the progression
of Parkinson’s disease.
Ceramides, glucosyl-ceramides, and lactosyl-ceramides
were increased in the Pink1−/− olfactory bulb starting from
9 months on (Fig. 2d). Analysis of variance for repeated
measurements revealed significant differences between
genotypes (F (1:20) = 7297; P = 0.0137) and for the inter-
action “ceramide by genotype” (F (10:200) = 4.558;
P < 0.0001). Subsequent post-hoc analyses for each
ceramide and sphingolipid separately were significant for
Cer18:0 (P < 0.0001), LacCer24:1 (P = 0.0285), and
GluCer18:0 (P = 0.0042). For individual ceramides, there
was no site-specific significant progression with increasing
age, but analysis of log-2 transformed total ceramides
revealed age-dependent differences. In wildtype animals,
log-2 Cers linearly increased over time, but in Pink1−/−,
levels were already increased at 9 months and remained at
this elevated level, so that genotype-dependent differences
were strongest in young mice (2-way ANOVA “genotype x
age” for genotype F (1, 54) = 16.98, P = 0.0001; for the
interaction F (2, 54) = 2.531, P = 0.089) (Fig. 2e). Hence,
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the observed increase of ceramide levels is strongly suggest-
ive of ongoing neuro-inflammation in the brain starting in
young adulthood, particularly in the olfactory bulb—a brain
area which is among the first to be affected by Parkinson’s
disease.
Global transcriptome profile of Pink1−/− mouse neuron-
rich primary cultures
Given that PINK1 is important for stress responses
[5, 6, 13], and in view of the enhanced release of
inflammatory cytokines from acutely prepared Pink1
−/− brain slices [84], we decided to study very young
Pink1−/− neuron-rich primary culture in vitro—where
the previous mechanical dissection, the lack of glial sup-
port, and the presence of the toxin cytosine arabinoside
(cytarabine) exert combined stress [85, 86]. Hence, murine
neuron-rich primary cultures were established at postnatal
age and maintained for 12 days to assess early effects of
PINK1 deficiency on global transcriptome readouts
(Additional file 9: Table S7). Given that genomic insertion
Fig. 2 Astroglial and microglial response, as well as ceramide accumulation in Pink1-deficient mouse brain. The immunohistochemical staining of GFAP as
astroglial marker and Iba1 as microglial marker in Pink1−/−mouse brain at the age of 18 months demonstrated a mild increase in the frequency of
inflammatory glial reactions, best detectable along the corticospinal tract where it traverses the brainstem (a, 10× objective used) and the striatal region
(b, 4× objective). c The elevated frequency of this glial response was demonstrated in cell counts for astrogliosis and microgliosis in relation to total cells
per area (nuclear counterstain) in 18-month-old brains that underwent automated immunohistochemistry of GFAP1 and Iba1 demonstrated region-specific
mild effects. The substantia nigra was less affected than areas that are penetrated by myelinated axons. Data are displayed as bar graphs, illustrating mean
values of serial sectioned and randomly picked mouse brain areas. Brain graphs show standard error of the mean (SEM) of technical replicates with at least
n = 3 sections per genotype per region. Statistical analysis would be inappropriate, given that the serial sections were from too few inbred animals. d
Increased levels of ceramides, glucosyl-ceramides, and lactosyl-ceramides were observed by liquid chromatography tandem mass spectrometry in the
olfactory bulb summarized for ages of 9–13 months, 17 months, and 21 months (n = 3 or 4 mice of each age and genotype). The scatter shows individual
mice, the line is the mean, and whiskers show the standard deviation. e Log2-transformed total ceramides across brain regions reveal age-dependent
differences between genotype, i.e., an increase over time in wildtype mice that contrast with very high levels in younger Pink1−/− mice which remain at this
elevated level. Two-way ANOVA differed significantly between genotypes. Asterisks illustrate the significance (multivariate ANOVA, subsequent t test for each
lipid, Holm-Šidák adjusted p values, *p < 0.05, **p < 0.01, ***p < 0.001)
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events may influence the expression of neighboring genes
across a distance of 3 MegaBases [87], it was reassuring that
only one dysregulated transcript, Nipal3, was encoded in
the vicinity of Pink1.
Two findings had obvious credibility, but limited novelty,
namely the dysregulation of Dram1 and Ret mRNA levels.
Ordered by significance, the Dram1 (the abbreviation
stands for DNA-damage regulated autophagy modulator 1)
transcript 1.7-fold upregulation was the strongest early
change after Pink1 loss (p value ≈ 0.0001). Similar to
PINK1, DRAM1 is connected to the pathway of selective
autophagy, since it promotes the targeting of mycobacteria
to degradation [88], and is thus contributing to innate
immunity responses. DRAM1 mRNA is selectively
downregulated in brain tissue of PD patients [89]. A
similarly meaningful observation was the 1.7-fold upregula-
tion of Ret (proto-oncogene RET receptor tyrosine kinase)
(p value ≈ 0.001). RET trophic receptor signaling was
already shown to rescue histological and biochemical
phenotypes of Pink1 deletion in flies [15]. In a human
neuroblastoma cell line, the administration of its receptor
ligand GDNF compensates morphological and bioenergetic
deficits of PINK1-deficient cells without affecting
mitophagy. Furthermore, GDNF stimulation rescued mito-
chondrial defects in PARKIN-deficient cells, while the loss
of dopaminergic midbrain neurons in aged RET-deficient
animals was rescued by PARKIN overexpression and exac-
erbated by PARKIN deficiency [16]. Intriguingly, GDNF
transfected macrophages significantly ameliorated neuroin-
flammation and neurodegeneration in a PD mouse model
[90]. Thus, the Ret mRNA upregulation in Pink1-deficient
primary neuron cultures after dissociation stress may also
form part of the neuroinflammatory response pathway.
In addition to the known candidates, we observed a re-
markable and novel enrichment of additional factors in-
volved in antiviral state, innate immunity, and
neuroinflammation (Additional file 9: Table S7) including
Gin1 (gypsy retrotransposon integrase 1) [91], Hmox1
(Heme oxygenase 1) [92, 93], Hebp1 (Heme-binding pro-
tein 1) [94], Snx16 (Sorting nexin 16) [95], Timp1 (Tissue
inhibitor of metalloproteinase 1) [96, 97], Dnmt2 (DNA
methyltransferase 2) [98–101], Rsad2 (Radical S-adenosyl
methionine domain containing 2 = Viperin) [102–106],
Adamts4 (a disintegrin-like and metallopeptidase—reproly-
sin type—with thrombospondin type 1 motif, 4) [107–109],
Csde1 (Cold shock domain containing E1, RNA bind-
ing = UNR) [110], and Ifit3 (interferon-induced protein
with tetratricopeptide repeats 3) [111, 112].
Further enrichments in the transcriptome profile were
apparent for DNA/RNA-quality control and for antioxi-
dant/hypoxia factors. The DNA/RNA quality control fac-
tors included Zfp148, Cdk7, Tia1, Mbd1, Mus81, Mat2a,
and Hipk2 [113–127]. The hypoxia/antioxidant factors,
which are credible in view of the well-documented
oxidative stress and bioenergetics deficit in PINK1-
deficient cells [21, 41], included Srxn1, Hlf, Steap1,Tsga10,
and Hipk2 [126–132].
Intriguingly, Foxp1 (Forkhead Box P1) showed a 1.7-fold
downregulation (p value ≈ 0.03). This differentiation factor
of midbrain dopaminergic neurons was previously found
downregulated also in mice with knock-out of alpha-synu-
clein, while its upregulation was documented in mice with
transgenic overexpression of A53T-alpha-synuclein, which
model the PARK1 and PARK4 variants of PD [30, 31, 133].
Thus, the dysregulation of Foxp1 transcripts levels appears
to respond both to acute stress and to constant mutations
of at least two PD genes.
Overall, already at neonatal stages, a significant expres-
sion dysregulation of innate immunity factors in Pink1−/−
primary neurons became apparent under in vitro stress
conditions.
Transcript analysis in the brain from adult Pink1−/− mice
with chronic A53T-SNCA stress
For independent validation of these observations, and to
exclude that a microbial infection of the cultures had pro-
duced artifacts, we next studied the transcript levels of
candidate genes by qPCR in brain homogenate extracts
from independent animals. Given that the stress-evoked
observations in primary Pink1−/− neurons were not evi-
dent in global transcriptome screenings of single-mutant
Pink1−/− mouse brains even at old age [20], we reasoned
that additional challenges may be necessary to manifest
PINK1-dependent stress response dysregulations. Thus,
we studied double-mutant mice, where the Pink1−/− is
combined with 1.5-fold overexpression of A53T-alpha-
synuclein (SNCA) selectively in neurons as a trigger of
Parkinsonian pathology and as a genetic interactor of
PINK1 [19, 20]. These double-mutant mice show a poten-
tiated phenotype with appearance of Lewy-like inclusion
bodies and with lethality from the age of 14 months
onward [20]. The global transcriptome in several brain re-
gions throughout their lifespan was previously compared
to single mutant Pink1−/− mice, and the data are publically
available in a database [20]. It has always been our
experience that the heterogeneity of neuron populations
in midbrain/brainstem and the dissection variance make it
very difficult to demonstrate subtle expression changes.
In midbrain from adult double-mutant Pink1−/−+A53T-
SNCA mice at the age of 18 months, a significant 1.16-fold
upregulation for Mapk9 (p value = 0.0007), a significant
2.15-fold upregulation for Rsad2 (p value = 0.0007), a trend
towards significance (p value = 0.08) for the 0.87-fold
downregulation (a dysregulation so subtle that it would
usually be deemed irrelevant) of Hebp1, and a significant
1.92-fold upregulation for Tnf alpha were observed
(p value = 0.03) (see Additional file 10: Fig. S3).
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Thus, also in midbrain, the PINK1 deficiency led to
dysregulated expression levels of key factors in the anti-
microbial defense, when an additional challenge repre-
sented by mutant A53T-alpha-synuclein exceeded the
allostatic threshold.
Systematic study of antiviral factor mRNAs in human
PINK1-knockdown neuroblastoma cells after acute
starvation
We decided to test in vitro whether (I) similar observations
indeed occur in neural cells or have to be attributed to
microglia, (II) the mouse data can be translated to human,
(III) transient changes can be defined after acute stress, and
(IV) trophic and nutrient deprivation stress with concomi-
tant autophagy can trigger these stress response changes,
always in dependence on PINK1 deficiency. The starvation
stress was initially chosen rather than established Parkin-
sonian toxins like MPTP or CCCP [6, 134], since PINK1
was recently shown to respond to mutations in ATXN2,
which is a known starvation response factor [135–138], and
in view of the known transcriptional induction of PINK1
and PARKIN during trophic deprivation [13]. The human
neuroblastoma cell line SH-SY5Y with stable lentiviral
knockdown (KD) of PINK1 versus a non-target (NT)
control sequence were subjected to acute starvation by
changing the culture conditions from RPMI medium with
10% Fetal Calf Serum (FCS) to HBSS medium (low glucose,
no amino acids) without FCS. The transcriptional regula-
tion was documented over 2 days for several key factors of
the antiviral defense by qPCR. The overview on this sys-
tematic survey of the mitochondria-associated antiviral
defense pathway is represented in Fig. 3a, with blue color il-
lustrating deficiency and PINK1-dependent downregula-
tion, while red color illustrates PINK1-dependent
upregulation. The KD was stable, since PINK1 mRNA in
this cell line was reduced to 30% before stress and to 9%
after stress at the 16-h time point (Fig. 3b). As described,
the starvation induced PINK1 mRNA in a phasic manner
with a peak at 12 h [13]. Similar to the previous findings in
Pink1−/− mice, an upregulation of RSAD2 and a downregu-
lation of HEBP1 were observed in the starving PINK1-defi-
cient neuroblastoma cells. RSAD2 was induced up to
1.6-fold in control cells, and this response was potentiated
by 46% in PINK1-KD cells, with strong significance at 2
and 4 h (Fig. 3c). The up to 3.3-fold induction of HEBP1
levels in control cells was significantly diminished at 16 h in
PINK1-KD cells (Fig. 3d).
Systematic further assessment of the innate immunity
pathway revealed further regulations, with PINK1-
deficiency modulating the alterations caused by starva-
tion. A supersensitive transcriptional upregulation was
observed not only for RSAD2 but also for TBK1 and
IRF3. TBK1 was induced up to 1.9-fold in control cells,
and this induction was further increased to 2.2-fold in
PINK1-KD cells, with strong significance at 4, 8, 24, and
48 h (Fig. 3e). Similarly, IRF3 levels were elevated up to
2.2-fold in control cells, and this elevation was exacer-
bated to 2.4-fold in PINK1-KD cells with strong signifi-
cance at 24 and 48 h (Fig. 3f ).
In contrast, a downregulation was observed for a known
posttranslational modification target of PINK1/PARKIN
signaling, mitochondrial MFN1. The 2.0-fold starvation-
triggered induction of MFN1 transcript was blunted in
PINK1-KD cells by 32%, with strong significance at 12 and
16 h (Fig. 3g). Starvation triggered an initial short upregu-
lation and later consistent downregulation of IFIT3 levels
to 15% in control cells. In PINK1-KD cells, a strong down-
regulation of IFIT3 levels appeared already at 2 h and was
stably diminished further to 6% of control at 48 h, with
significant differences between NT and PINK1-KD cells
from 2 to 16 h (Fig. 3h). The starvation-triggered up to
1.7-fold induction of IFIT1 levels was also diminished in
PINK1-KD cells by 41% with strong significance at 8, 12,
and 16 h (Fig. 3i). Finally, the starvation-triggered almost
3.7-fold induction of the mitochondria-associated innate
immunity factor MAVS was blunted in PINK1-KD cells by
40%, with strong significance at 12 and 16 h (Fig. 3j).
No significant dysregulation was documented for the
transcript levels of TMEM173 (STING) as an endoplasmic
reticulum-associated antiviral factor (data not shown).
Given that experimental testing of multiple mRNAs at
multiple time-points followed by statistical evaluation via
Student’s t tests will exaggerate the significance, an adjust-
ment of the significance threshold according to Bonferroni
is useful, by dividing the nominal p values indicated in
each panel of Fig. 3 through the number of analyses done.
After this correction, the downregulation of PINK1,
MFN1, MAVS, IFIT1, and IFIT3 and the upregulation of
RSAD2 and TBK1 remain significant as particularly robust
findings.
In order to provide a time-correlation and comparison
with autophagy factors that are also regulated by starva-
tion, the curves for LRRK2 and SQSTM1 are shown as
well (Fig. 3k–m), given that LRRK2 is a positive regulator
of inflammation and autophagy, with mutations that trig-
ger autosomal dominant Parkinson’s disease; SQSTM1
(sequestosome 1 = p62) was studied as an adaptor
between the autophagy machinery and ubiquitinated
cargo, whose mutation cause neurodegenerative disorders
such as motor neuron disease. A significant indirect correl-
ation was observed again between the PINK1-deficiency
and an exacerbated induction of LRRK2 transcript levels, as
previously reported for fibroblasts and neuronal cells de-
rived from PARK6 patients [139].
Overall, the data confirm that key factors of the anti-
microbial response are modulated in their transcrip-
tional regulation by PINK1 in human neural cells after
acute starvation stress.





Fig. 3 (See legend on next page.)
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Systematic study of antiviral factor mRNAs in human
PINK1-knockdown neuroblastoma cells after triggering
mitophagy by FCCP
To further assess if indeed mitochondrial dysfunction
underlies changes in innate immunity, we used the un-
coupling drug FCCP to trigger mitophagy and then
study the transcriptional response of the above key
factors in PINK1-knockdown and control SH-SY5Y
neuroblastoma cells. Mitophagy needs at least 12 h to
occur and subsequent transcriptional responses require
additional time. Therefore, the RNA extraction and
qPCR analyses were performed later than in the previous
experiment, at 24 h after drug administration. As shown
in Additional file 11: Fig. S4 above, FCCP in SH-SY5Y
cells elicited a transcriptional induction of the mitochon-
dria associated factors PINK1, DDX58, and MAVS and
of TBK1, accompanied by a downregulation of the RNA
sensor IFIT1, in control cells. A significant difference be-
tween control cells and PINK1 knockdown cells after
FCCP treatment was only observed for MAVS, which
failed to be induced in the absence of PINK1. These data
confirm that key inflammatory factors respond to mito-
chondrial dysfunction and that particularly the levels of
the mitochondrial antiviral signaling factor MAVS de-
pend on PINK1 levels.
Systematic study of antiviral factor mRNAs in Pink1−/− murine
embryonal fibroblasts after triggering mitophagy by FCCP
treatment
Pink1−/− murine embryonal fibroblasts (MEFs) are a use-
ful tool to test if the presence of lentiviral knock-down
double-strand RNA in the human neuroblastoma cells
distorts the results and to test whether these effects
apply only to neuroinflammatory processes, or represent
responses of the innate immunity system of any cell also
outside the nervous system. Therefore, MEFs were sub-
jected to FCCP treatment and the transcriptional response
of the key antiviral factors was studied in the presence or
absence of PINK1. As shown in Additional file 11: Fig. S4
below, FCCP treatment of MEF cells after 24 h led to tran-
scriptional upregulation of murine Mavs, accompanied by
downregulation of Rsad2, Ddx58, Tbk1, Irf3, Mfn1, Ifit3,
and Ifit1, both in control WT cells and Pink1−/− cells.
Thus, again the mitochondrial antiviral signaling factor
Mavs showed a selective dependence on mitochondrial
dysfunction, whereas the levels of all other antiviral key
factors decreased in parallel to the FCCP-triggered
autophagic elimination of mitochondria. Fibroblasts
tolerate a reduction of mitochondrial mass by prominent
glycolysis, whereas neuronal cells depend on mitochondria
and will compensate mitophagy with mitochondrial
(See figure on previous page.)
Fig. 3 Systematic analysis of key factors in the mitochondria-associated innate immunity pathway, using acute starvation of human SH-SY5Y neuroblastoma
cells to reveal the transcriptional regulation of stress responses and their dependence on PINK1. Transcript levels were documented in control non-target
knock-down (NT-KD) versus PINK1-knock-down (PINK1-KD) cells for the following inflammatory factors. a Summary scheme on the detection of pathogen
DNA/RNA in the cytosol and the mitochondria-associated triggering of innate immunity, as altered during starvation by PINK1. Viral RNA (ssRNA or dsRNA) is
recognized in the cytosol by helicase RIG-I and MDA5. This triggers the dimerization of MAVS in the outer mitochondrial membrane (OMM) which recruits
transactivators (such as TRADD, TRAF, IKK family) leading to nuclear translocation of phosphorylated IRF3, IRF7, and NF-κB and promoting the transcription of
IFN stimulated genes and pro-inflammatory cytokines, respectively. Effector molecules such as IFIT1, IFIT2, IFIT3, and RSAD2 (viperin) inhibit virus DNA/RNA
replication. IFIT3 also functions as a scaffold to facilitate interaction between MAVS and TBK1 and represents a positive feedback of DDX58 (RIG-I) signaling
through MAVS. Low ΔΨm or decreased ROS inhibit MAVS-mediated signaling. Mitochondria cooperate with the endoplasmic reticulum (ER) to regulate lipid
synthesis and antiviral signaling at the mitochondria-associated membranes (MAM), possibly by interactions of MAVS/MFN1 with TMEM173 (STING). MFN1
leads to the redistribution of MAVS along mitochondria and a fusion of the mitochondrial network that promotes the interaction between MAVS and STING.
Low energy induces the localization of PINK1 to the OMM and recruitment of PARKIN from the cytosol, which is the signal for dysfunctional mitochondria
to be digested in the autophagosome. Abbreviations: 5′ ppp 5′ triphosphate, ΔΨm mitochondrial membrane potential, IκB inhibitor of κ light polypeptide
gene enhancer in B cells, IKK IκB Kinase, LC3II phosphatidylethanolamine conjugate of the autophagy-related protein LC3 (MAP1LC3), MDA5 melanoma
differentiation-associated gene 5, NF-κB nuclear factor κB, p62 sequestosome-1, adaptor between polyubiquitinated substrates and autophagic machinery,
PARKIN ubiquitin ligase, its loss-of-function leads to the PARK2 variant of Parkinson’s disease, RIG-1 (DDX58) retinoic acid-inducible gene-1 (DExD/H-Box RNA
Helicase 58), ROS reactive oxygen species, ssRNA/dsRNA single-stranded/double-stranded RNA, TMEM173 (STING) transmembrane Protein 173, TRADD tumor
necrosis factor receptor type 1 associated death domain protein, TRAF TNF-receptor-associated factor. b PINK1 (PTEN induced kinase 1) as a known
determinant of selective mitophagy and autosomal recessive Parkinson’s disease; HPRT1 (Hypoxanthine Phosphoribosyltransferase 1) as a loading control.
c RSAD2 (= viperin, radical S-adenosyl methionine domain containing 2) as an interferon-inducible lipid-droplet associated virus inhibitory factor. d HEBP1
(heme binding protein 1) that contains a natural ligand for formyl peptide receptor-like receptor 2. e TBK1 (TANK-binding kinase 1) that phosphorylates
interferon regulatory factors in response to toll-like receptor activation. f IRF3 (interferon regulatory factor 3) as a regulator of type I Interferon gene
transcription. g MFN1 (mitofusin 1) as PARKIN-dependent factor in mitochondrial dynamics and mitochondria-associated anti-microbial signaling. h IFIT3
(interferon-induced protein with tetratricopeptide repeats 3) as a detector of pathogen DNA/RNA. i IFIT1 (interferon-induced protein with tetratricopeptide
repeats 3) as a detector of pathogen DNA/RNA. j MAVS (mitochondria-associated viral sensor) as inducer of interferon-dependent long-term expression of
defense factors. k–m The levels of known autophagy factors during this starvation time course exhibited progressive consumption of p62 in spite of its
transcriptional induction, in parallel to a PINK1-modulated transcriptional induction of LRRK2. Four independent experiments compared their expression
during a nutrient and trophic deprivation time course triggered by a culture switch from RPMI growth medium to HBSS starvation medium. The bar graphs
show mean and standard error of the mean, illustrating the significance with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
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biogenesis [37]. Therefore, fibroblasts and neurons may
respond to FCCP with opposing regulations of
mitochondria-dependent innate immunity factor levels
even in control cells.
Systematic study of antiviral factor mRNAs in PINK1-
deficient cells after activating innate immunity with
poly(I:C) as a pathogenic RNA-analogue
In view of the strong PINK1-dependent dysregulation of
several sensors of pathogenic RNA and of an RNA-virus
budding suppressor, namely RSAD2, IFIT3, and IFIT1 in
the starvation experiment (Fig. 3c, h, i), we also stressed
both cell types (neuroblastoma and MEF cells) with
poly(I:C) as a pathogenic RNA-analogue and determined
the transcriptional response after 16 h (Fig. 4a). Neuroblast-
oma cells responded by massive inductions of RSAD2,
DDX58, IFIT3, and IFIT1, moderate induction of IRF3, and
a downregulation of PINK1. The additional knockdown of
PINK1 significantly blunted the upregulations of RSAD2
and DDX58 in SH-SY5Y cells. In MEF cells, again a down-
regulation of Pink1 was found, now paralleled by moderate
downregulation of the other two mitochondrial outer mem-
brane factors, Mfn1 and Mavs. Massive inductions of
Rsad2, Ddx58, Ifit3, and Ifit1 reoccurred, now with a mod-
erate increase of Tbk1. The Pink1 deletion significantly
blunted the upregulations of Rsad2 and Ifit3 in MEFs.
The substantial upregulations of RNA sensors and their
modulation by PINK1 encouraged us to attempt validating
these effects also at the protein level, so quantitative im-
munoblots were performed (Fig. 4b). In neuroblastoma
cells, the poly(I:C) triggered inductions were significantly
blunted by PINK1 knockdown for RSAD2, DDX58, IFIT3,
and IFIT1. In comparison, MEF cells also responded by
strong inductions to poly(I:C), but the PINK1-dependent
reductions of RSAD2, DDX58, and IFIT3 were not signifi-
cant. IFIT1 could not be analyzed, since the available
antibodies in our hands recognized only the human, but
not the murine variant. Overall, these data clearly establish
PINK1 as enhancer of anti-microbial responses and
particularly of RNA sensors.
Expression analysis of key antiviral factors in primary skin
fibroblasts from PARK6 patients
Particularly strong and early PINK1-dependent effects were
further assessed by qPCR in unstressed primary skin fibro-
blasts from PARK6 patients versus control individuals,
which were previously characterized regarding mitochon-
drial dysfunction and expression profiles and were found to
constitute a useful model of PD [1, 5, 12, 19, 41–43]. In the
fibroblasts of homozygous PARK6 patients, IFIT3 transcript
was reduced to 31% (p = 0.0059), while RSAD2 transcript
was increased to 307% (p = 0.044) (Fig. 5a). These data in
fibroblasts from manifest PARK6 patients at advanced age
confirmed the previous findings in starving neuroblastoma
cells, verifying that the loss of function of PINK1 leads to a
deficit of the mitochondria-associated antiviral RNA sensor
IFIT3, in parallel to a supersensitive induction of down-
stream RSAD2 (viperin) as an inhibitor of many RNA and
DNA viruses. In quantitative immunoblots, IFIT3 protein
was reduced to 0.27-fold (±0.10, p = 0.03) (Fig. 5b). The
RSAD2 protein levels were not significantly changed within
this analysis of three patients versus three control samples.
These data confirm that the IFIT3 mRNA downregulation
is not offset by compensatory molecular efforts, but instead
is translated into a deficit of this key antiviral factor at the
protein level, thus altering innate immunity responses at
the advanced age of manifest PARK6 patients.
Discussion
The progression of pathology in PD tissues and its animal
and cell models is being documented intensively at the
clinical, histology, imaging, neurophysiology, and molecu-
lar levels, especially in cases with monogenic pathogenesis
[140–143]. There is an urgent need of risk biomarkers for
the presymptomatic detection and preventive therapy, as
well as of progression biomarkers for the objective quanti-
fication of disease severity and of therapeutic benefits.
However, the brain tissue from patients is available only at
final stages of disease, and most available autopsies are
from genetically undefined and therefore heterogeneous
variants of PD. Conversely, the peripheral cells and tissues
from patients reflect only some initial abnormalities of
pathogenesis [19, 41, 43] and do not progress to a selective
cell death. Thus, the analysis of brain tissue from postnatal
age until the multimorbid old age, e.g., in PINK1-mutant
or alpha-synuclein-mutant mice [30, 133, 144, 145], holds
great promise. Several studies in the past have employed
unbiased global OMICS approaches to screen the activity
of practically all known genes [20–22, 29, 30].
Nonetheless, in spite of the enormous recent progress in
PD genetics and in the characterization of corresponding
disease models, it has remained difficult to identify and es-
tablish individual molecular progression biomarkers. It
was expected that the levels of any such molecular marker
would correlate with the severity of disease, similar to
hemoglobin levels in anemia or to creatinine levels in
kidney dysfunction.
Our novel progression analysis of global transcriptome
profiles in PINK1-deficient brain tissue across lifespan
now indicates that subsequent stages of pathology are
characterized by the involvement of increasing numbers
of subtly dysregulated pathways rather than stronger
expression anomalies of individual candidates. This in
vivo approach identified several pathways to be promin-
ently PINK1-dependent, in good agreement with previ-
ous in vitro findings in most cases. Importantly, for the
first time, we establish a temporal order and provide a
quantitative value for the significance of each pathway.
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Fig. 4 Poly(I:C) triggered expression responses of innate immunity factors in dependence on PINK1. a Transcriptional changes: SH-SY5Y human
neuroblastoma (above) and murine embryonal fibroblast cells (below) were studied regarding the expression of key inflammatory factors in
untreated versus drug-treated cells, comparing control with PINK1-deficiency (n = 8 each for RSAD2, DDX58, IFIT3, and IFIT1 in man, and n = 4
each for Rsad2, Ddx58, Ifit3, Ifit1 in mouse). TBP transcript levels were used as loading controls to normalize the data. The bar graphs show mean
and standard error of the mean, illustrating the significance with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). b Protein changes:
representative quantitative immunoblots and their statistical evaluation in bar graphs (n = 3 WT versus 4 mutant) showed a massive induction of
the RNA sensors RSAD2, DDX58, IFIT3 (in human as well as mouse), and IFIT1 (human-specific antibody), which was blunted in PINK1-deficient
cells (significance demonstrable only in neural cells). The beta-Actin protein level was used as loading control to normalize the
quantitative results
Fig. 5 Altered antiviral factors in primary skin fibroblasts from PARK6 patients. a The levels of RSAD2, DDX58, and IFIT3 transcript as well as (b) the levels
of RSAD2, DDX58, and IFIT3 protein were assessed in unstressed cells from 3 homozygous G309D-PINK1 PD patients versus matched controls. The bar
graphs show mean and standard error of the mean, illustrating the significance with asterisks (* p < 0.05 and ** p < 0.01)
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In the scenario documented, a first disease stage is
defined by a mild adaptation of the nuclear splicing
machinery, which persists without increase throughout all
ages. This is completely novel evidence; the notion of a spli-
cing adaptation to PINK1-deficiency is currently supported
only by an OMICS study into posttranslational modifica-
tions of the brain in a genetic mouse model of PD, where a
strongly altered arginine-methylation of the splicing factor
PSF was observed, caused either by PINK1 deficiency or by
alpha-synuclein gain of function [22]. The transcriptional
dysregulation of Srsf10 as a spliceosome component was
reproduced by qPCR. Given that spliceosomal alteration is
a constant feature in Pink1−/− brain and that Ube3a and
Mapk8 are regulated by alternative splicing, we investigated
the dysregulation of their splice isoforms and demonstrated
a selective effect on the shorter splice isoform of UBE3A, a
ubiquitination enzyme responsible for alpha-synuclein
degradation [59].
A second disease stage shows manifest anomalies in
the ubiquitin-dependent degradation of proteins and
in the protein processing at the endoplasmic
reticulum (ER). These data are in excellent agreement
with the established role of PINK1 as a ubiquitin
kinase [146]. Scarce evidence exists until now on the
role of PINK1 as a modifier of ER stress [147–151],
but our microarray biomathematics support the no-
tion that alterations at the ER appear earlier than
mitophagy and have stronger significance. Indeed, the
transcriptional dysregulation of Creb3 and Nfkbia as
ER stress and inflammation factors was similarly
reproduced by qPCR as the dysregulation of Ube3a as
a component of ubiquitination pathways. Thus, both
the ubiquitin kinase effects and the early alteration of
widespread protein processing support a novel con-
cept, where PINK1 has a general role for subcellular
degradation rather than a function restricted to the
selective elimination of dysfunctional mitochondria.
Vesicular and lysosomal pathway dysregulations are
more prominent at early ages upon GSEA bioinfor-
matics than mitochondrial pathways.
A third stage, at old age in the Pink1−/− mouse, cere-
bellar tissue shows no change of the effect size in
expression dysregulation in parallel with the progression
of pathology, e.g., for the components of the splicing
machinery. Instead, the number of dysregulated factors
and pathways, the significance of the intracellular
membrane-bounded organelle enrichment, and the
appearance of altered neurotransmission, mitophagy, anti-
microbial, and neuroinflammatory profiles were clearly
age-associated. Our experimental validation of increased
Mapk8 and Nfkbia transcript levels is in agreement with a
previous report about Pink1−/− astrocyte JNK1 signaling
[51] and with evidence for an interaction between PINK1
and the NF-kappaB pathway [152–156].
Indeed, neuroinflammation is well documented in
late stages of PD [157–161]. Initially, it was thought
to be triggered by the debris resulting from neuronal
loss [162]. Further detailed study of genetic mouse
and cell models demonstrated the neuroinflammation
to precede neuronal loss [163], and current concepts
propose alpha-synuclein aggregates and their extracel-
lular extrusion to act as triggers of toll-like-receptor
upregulation, cytokine release, and microglia activa-
tion [164–175]. In contrast, our observations demon-
strate the enrichment of neuroinflammatory
dysregulations quite early in the disease course, in
brain tissues where alpha-synuclein aggregation was
not detectable [29]. The concept that mitochondrial
dysfunction alone is sufficient to modulate the innate
immunity factors was also supported by our FCCP
and poly(I:C) experiments in human neuroblastoma
cells and murine embryonal fibroblasts. These data
showed the mitochondrial antiviral signaling factor
MAVS to be selectively responsive to proton gradient
and PINK1 changes, and the induction of DDX58,
IFIT3 and IFIT1 as sensors of pathogenic dsRNA and
of RSAD2 as viral replication suppressor to be modi-
fied by PINK1.
Thus, we suggest that innate immunity is triggered within
neurons via PINK1-associated mitochondrial dysfunction.
Indeed, evidence has accumulated over the past 5 years that
dysfunctional mitochondria are releasing damage-associated
molecular patterns (DAMPs), e.g., the hypomethylated
DNA/RNA and formylated peptides which are
characteristic for bacteria and the mitochondrial endosym-
biont [176, 177]. This release triggers the innate immune
system and in particular a mitochondria-associated pathway
of defense against abnormal DNA/RNA [178–180]. In good
compatibility with this concept, recent findings confirm that
neuroinflammation in PD can be modulated by the formyl-
peptide receptors [181]. We have lately shown in another
human hereditary disorder, Perrault syndrome, that mito-
chondrial dysfunction can be a strong trigger of the innate
immune system via mtDNA accumulation, with subsequent
early-onset infertility, growth deficits, and age-associated
neurodegeneration [38]. In the pathways involved, the IFIT
protein family together with DDX58 (RIG-I) is responsible
of the recognition of pathogenic DNA/RNA in the cytosol,
while RSAD2 (viperin) inhibits viral budding from mem-
branes via lipid raft alteration. The mitochondria-associated
MAVS/MFN1/IFIT3 complex then triggers phosphorylation
and ubiquitination events that ultimately lead to NFkappaB-
mediated nuclear regulations and to TBK1/IRF3-mediated
interferon signals for neighboring cells [111, 182] (Fig. 3a).
Of course, the resulting stress metabolism and impairment
of cell growth together with alterations of mitochondrial
calcium buffering would influence synaptic plasticity and
excitability, contributing to the known alterations of calcium
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homeostasis and neural transmission in PARK6 mouse
models [44, 143, 183].
A similar mechanism could operate in PINK1 and
PARKIN deficient cells, which are being used as
models of PD and are known to have an impairment
of selective mitophagy, as was suggested by a recent
report of high visibility that PARKIN also mediates
resistance to microbial invasion [18]. The PINK1-
dependent subtle molecular mismanagement of
variably reoccurring life events such as infections (in
our data mimicked by polyI:C) or hunger (mimicked
by HBSS medium) may determine, if the clinical
manifestation of Parkinson’s disease occurs early or
late in life. It was recently demonstrated that the
downregulation of Ataxin-2, a lipid-storage factor and
mTOR-repressor upstream from PINK1, may post-
pone death in a mouse model of motor neuron dis-
ease from 20 to over 300 days [135, 184–186].
The innate immunity problems of PINK1-deficient cells
become detectable even at the postnatal age upon the
presence of a stressor. Stress exposure of Pink1−/− primary
neuron-rich cultures leads to the significant expression
dysregulation of the abnormal DNA/RNA sensor Ifit3 and
the iron-sulfur-cluster detector Rsad2, confirmed in
Pink1-KO+A53T-SNCA double mutant brain, in human
neuroblastoma cells, in Pink1−/− MEFs, and in PARK6
patient skin fibroblasts. The starvation dataset links
PINK1 deficiency to a transcriptional downregulation of
mitochondria-associated innate immunity factors such as
MAVS, MFN1, and IFIT3, and the FCCP dataset shows
altered expression of MAVS and MFN in MEFs and a
PINK1-dependent blunting of MAVS induction in
SH-SY5Y cells. MFN1 and MAVS are localized to the
mitochondrial outer membrane, respond to an alteration
in the mitochondrial proton gradient, and mediate the
elimination of dysfunctional mitochondria via autophagy
[187–190]. In addition, MAVS expression also modulates
antiviral signaling via IFIT3 [112]. The starvation dataset
also indicates a parallel PINK1-dependent transcriptional
induction of downstream innate immunity factors such as
TBK1, IRF3, and RSAD2. As shown in the poly(I:C) data-
set at transcript and protein level, the regulation of IFIT3
and RSAD2 is altered by PINK1 deficiency. RSAD2
upregulation and mitochondrial relocalization triggers the
lipogenesis for viral envelope formation [191, 192].
Beyond the established role of PINK1 for selective mito-
phagy, our novel data therefore indicate that PINK1 also
modulates the mitochondria-associated anti-microbial
defense pathway.
The changes in very young Pink1−/− brain and
Pink1−/− cells are perfectly compatible with previous
in vitro observations [84, 153, 154, 193–198].
Importantly, a highly visible publication was made
during the final stage of our project, which reported
PINK1 and Parkin in murine macrophages and fibro-
blasts to repress an immune-response eliciting path-
way via the trafficking of mitochondrial-derived-vesicles,
but not via mitophagy [199]. The present data from Pink1
−/− mouse brain, human neuroblastoma cells, and patient
fibroblasts serve as additional corroboration in vivo, pro-
viding a spatio-temporal framework and identifying cru-
cial molecular mediators.
Still, as an important caveat, we have to mention
several limitations of our findings: (I) Various tech-
nical approaches were focused on different brain re-
gions. The previously published global transcriptome
profiles had focused on midbrain/brainstem, which
were selected because they are responsible for the
characteristic mid-stage motor deficit of Parkinson’s
disease. The re-assessment of these data showed these
regions to be less informative within the 2-year life-
span of mice than the cerebellum. Consequently, for
a deeper understanding of the subtle early conse-
quences of Pink1-ablation, we focused the studies of
histology and ceramides on the brainstem and
olfactory bulb, where Parkinson’s disease starts.
Furthermore, demonstration of the expected glial
pathology uncovered a preferential affection of mye-
linated tracts. Thus, at present, it is cumbersome to
extrapolate the expression data and other findings
into a coherent picture of phenomenology and path-
ology progression in time and space, integrating ob-
servations from mouse and man, so further analyses
in-depth are needed. (II) The impaired response of
Pink1−/−-deficient cells against polyI:C suggests a vul-
nerability towards viral infections. Although we
present suggestive data at the transcript, protein, and
cellular level, with several artificial stressors, this issue
can only unequivocally be proven once Pink1−/− or-
ganisms are exposed to virus in future experiments,
with quantification of viability and propagation rates.
Conclusion
Our present findings support the concept that neuroin-
flammation in PD may occur long before neuronal loss
and before the formation of alpha-synuclein aggregates.
PINK1-mediated dysregulations of antimicrobial defense
and dysfunctional mitochondria are activating the innate
immunity.
The neuroinflammatory profile appeared in Pink1-
deficient mouse brain after earlier ubiquitination and
ER-associated degradation alterations, so these data
might define markers of disease progression. Although
PINK1-mutations are a rare cause of PD, PINK1 is
upstream of several other Parkinson’s disease genes
and its inactivity results in specific mitochondrial dysfunc-
tions as a trigger for the selective neurodegenerative
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pattern that is frequent [200–203], so our findings are
probably relevant for the multifactorial sporadic old-age
patients with PD.
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Additional file 1: Table S1. Global transcriptome profile of Pink1−/− brain
regions (C = cerebellum, M = midbrain, S = striatum) across the mouse
lifespan (6 W = 6 weeks, 24 W = 24 weeks = 6 months, 18 M = 18 months),
showing all expression dysregulations which were consistent in all regions
at all ages with significance (multiple testing adjusted p value <0.05). ID
identifies the Affymetrix microarray chip probe. AveExpr quantifies the
average expression strength among the tissues and ages for each transcript.
F, P value, and AdjPvalue refer to statistical values. For each column, 3
mutant versus 3 WT tissues were analyzed to represent a specific brain
region and age. (XLS 27 kb)
Additional file 2: Fig. S1. Global transcriptome profile of Pink1-deficient
mouse cerebellar tissue at ages 6 weeks (A), 6 months (B), and 18 months
(C), illustrating the network with respect to interactions between the encoded
proteins, employing the STRING web-server multiple proteins algorithm.
(ZIP 11629 kb)
Additional file 3: Table S2. STRING bioinformatics assessment of all
significant changes, including subtle effects. Ranked list of the significant
transcript expression changes in PINK1-deficient mouse cerebellar tissue at
ages 6 weeks, 6 months, and 18 months, which were used as input for the
STRING analysis (A). Significant functional enrichments in the protein-protein-
interaction network according to the STRING database is shown regarding GO
Cellular component at 6 weeks with all factors of AdjPvalue <0.05 (B),
6 months with all factors of AdjPvalue <0.05 (C), and 18 months with all
factors of AdjPvalue <0.01, with the term “intracellular membrane-bounded
organelle” being prominent at all 3 ages (D). Prominent enrichments were
highlighted in yellow color. In GO Molecular Process at 18 months with all
factors of AdjPvalue <0.01 the relevance of stimulus- and stress-dependent
pathways is apparent, e.g., endoplasmic reticulum stress, and a significant
enrichment of mitophagy factors appears here in lines 495 and 518 (E).
Among KEGG pathways at 18 months with all factors of AdjPvalue <0.01, the
highest ranked pathways include “MAPK signaling”, “Ubiquitin-mediated
proteolysis”, “Protein processing in endoplasmic reticulum” and “Bacterial
invasion of epithelial cells” (F). Orange color was used to highlight some
MAPK-dependent synaptic signaling pathways with significant enrichment,
purple color was used for ubiquitination and protein processing pathways,
green color was used for neuroinflammation pathways. (ZIP 366 kb)
Additional file 4: Table S3. STRING bioinformatics assessment with high
stringency of only >1.5-fold downregulations with significance. Ranked KEGG
pathway dysregulations are shown for cerebellum at each age. The prominent
MAPK signaling is highlighted in purple color, neuroinflammation pathways in
red, ubiquitination pathways in blue, endoplasmic reticulum stress response
pathways in orange, the mTOR signaling pathway (mimicked by starvation
stress during in vitro experiments) in dark gray, the vesicular pathways in light
brown. Subsequently, the interaction diagrams are shown for each age, with
components of the prominent MAPK signaling pathway highlighted in red
color. Finally, a heatmap shows all components of the MAPK signaling
pathway with their expression changes at each age in cerebellum, with clearly
progressive downregulation for several factors at the far end. (PDF 643 kb)
Additional file 5: Table S4. GSEA bioinformatics assessment—ranked
pathways by age. Ranked pathway dysregulations are shown separately on
different datasheets for the predefined Reactome and KEGG gene sets
regarding down- and upregulations, and progressive ages. Green background
colors for the nominal p value and the False Discovery Rate q values indicate
significance according to GSEA recommendations. Neuroinflammation
pathways are highlighted in red color, MAPK signaling in purple, Parkinson’s
disease in yellow, ubiquitination pathways in blue, endoplasmic reticulum
stress response pathways in orange, the mTOR signaling pathway (mimicked
by starvation stress during in vitro experiments) in dark gray, the vesicular
pathways in light brown. (XLSX 123 kb)
Additional file 6: Table S5. GSEA bioinformatics assessment—top dozen
pathways with components. In Pink1−/− cerebellum at the age of 18 months
the top dozen dysregulated KEGG pathways and the top dozen dysregulated
Reactome pathways are shown with individual components. The nominal p
values, false discovery rate q values and family wise error p values are shown
on top, the Rank Metric Score indicates the log2 expression values for each
factor, and YES reflects significance. (PDF 1540 kb)
Additional file 7: Table S6. GSEA bioinformatics assessment—heat
maps. Heat maps to illustrate the progression of expression dysregulation
for all individual components of selected pathways of relevance, namely
(A) the Reactome pathway “Negative regulators of RIG I and MDA5
signaling”, (B) the Reactome pathway “Antiviral mechanism by IFN
stimulated genes”, (C) the Reactome pathway “Antigen processing
ubiquitination proteasome degradation”, and (D) the Reactome pathway
“Activation of chaperone genes by Xbp1s”. (PDF 135 kb)
Additional file 8: Fig. S2. Transcript changes of Pink1-deficient mouse
cerebellar tissue at the age of 18 months in qPCR analyses represented in
bar graphs. (A) Significant downregulation of Srsf10 mRNA and
upregulations of Creb3 and Nfkbia mRNAs confirm the alteration within
spliceosomal, ER stress and neuroinflammation pathways. The significant
dysregulation of a Ube3a splice isoform is particularly interesting as a
potential target of the spliceosome alterations and in view of its role in
the degradation of alpha-synuclein. The scheme of Ube3a exon intron
structure with the location of different Taqman assays was adapted from
the Thermo Fisher Scientific internet site. (B) Significant upregulations of
Mapk8 mRNA at 3 different exon junctions, together with a scheme of
the Mapk8 exon intron structure and the location of 3 different Taqman
assays (modified from the Thermo Fisher Scientific internet site). Non-
significant changes of the MAPK phosphorylation cascade components
Mapk9 and Mapk14 mRNAs demonstrate the selectivity of transcriptional
regulation. Significant upregulations in the downstream nuclear transcription
regulators Creb3 and Nfkbia in the stress and inflammation response may
reflect biological responses to the Mapk8 upregulation. The bar graphs show
mean and standard error of the mean (10 Pink1−/− versus 10 WT), illustrating
the significance with asterisks (* p < 0.05 and ** p < 0.01). (TIFF 13007 kb)
Additional file 9: Table S7. PINK1-deficient transcriptome profile of
primary neuron cultures. Ranked list of significant expression changes in
global transcriptome profile of primary neuron cultures at 12 days after
dissection of brains at postnatal stage, taken from 3 Pink1−/− and 3 age-
and sex- matched WT controls from the same ancestors. FC = fold
change. (PDF 60 kb)
Additional file 10: Fig. S3. Transcription dysregulation of innate immunity
factors in the midbrain of 18-month-old Pink1-deficient mice with chronic
stress from A53T-SNCA overexpression. The levels of the stress-triggered pro--
inflammatory factor Mapk9, the lipid-droplet associated antiviral effector Rsad2
(viperin), the formylpeptide receptor activating Hebp1, and the
immunostimulant Tnf (TNF-alpha) transcripts were assessed in brain from adult
double mutant Pink1−/−+A53T-SNCA mice. These data corroborate the brain
tissue dysregulation of two factors that were previously found dysregulated in
the global transcriptome profile of Pink1−/− primary neuron cultures, taken
from postnatal mice and maintained in vitro over 12 days. Data are displayed
as bar graphs, illustrating mean values and standard error of the mean (SEM).
Tbp transcript levels were used as loading controls to normalize the data.
Significant differences were highlighted with asterisks (*p < 0.05; **p < 0.01;
***p < 0.001). (TIFF 17632 kb)
Additional file 11: Fig. S4. Transcriptional response of innate immunity
factors to 24 h treatment with uncoupling drug FCCP and subsequent
mitophagy, in dependence on PINK1. Three independent experiments in
SH-SY5Y human neuroblastoma (above) and murine embryonal fibroblast
cells (below) documented the expression of key inflammatory factors in
untreated versus drug-treated cells, comparing control with PINK1-
deficiency. The bar graphs show mean and standard error of the mean,
illustrating the significance with asterisks (* p < 0.05, ** p < 0.01, ***
p < 0.001). (TIFF 538 kb)
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